| Page | |||
|---|---|---|---|
| Trustees' | annual report |
||
| Independent examiner's report to the trustees |
|||
| Statement | of financial | activities | |
| Statement | of financial | position | |
| Notes to the financial statements |
| Registered | charity | name | Medical and Life | Sciences Research | Sciences Research | Fund |
|---|---|---|---|---|---|---|
| Charity registration | number | 1139383 | ||||
| Principal office | Medical and Life | Sciences Research | Fund | |||
| University of Warwick Science Park |
||||||
| Barclays Venture | Centre | |||||
| Sir William Lyons |
Road | |||||
| Coventry | ||||||
| The trustees | Prof C G Dowson | |||||
| Dr A Shehu | ||||||
| Prof C G Fink | ||||||
| Dr M Atkins | ||||||
| independent | examiner | Mr K C Varney - | ACMA of Varney | Barfield 8 Co. | ||
| 6 Corunna Court |
||||||
| Corunna Road |
||||||
| Warwick | ||||||
| CV34 5HQ |
| Ye | ar en | ded 5 April 2 | 022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2022 | 2021 | |||||||||
| Unrestricted | Restricted | |||||||||
| funcis | funds | Total funds | Total funds | |||||||
| Note | ||||||||||
| Income and | endowments | |||||||||
| Donations and |
legacies | 4 | 447,047 | 33,866 | 480,913 | 500,606 | ||||
| Total income | 447,047 | 33,866 | 480,913 | 500,606 | ||||||
| Expenditure | ||||||||||
| Expenditure | on | raising funds: | ||||||||
| Investment Expenditure on |
management costs charitable activities |
5 6,7 |
(1,140) (77,762) |
(33,866) | (1,140) (111,628) |
(94,068) | ||||
| Total expenditure | (78,902) | (33,866) | (112,768) | (94,068) | ||||||
| Net income | and net movement | in funds | 368,145 | 368,145 | 406,538 | |||||
| Reconciliation | offunds | |||||||||
| Total funds | brought forward |
519,518 | 4,811 | 524,329 | 117,791 | |||||
| Total funds | carried forward | 887,663 | 4,811 | 892,474 | 524,329 |
| State | ment of Financial Po | sition | |||
|---|---|---|---|---|---|
| 5April 2022 | |||||
| 2022 | 2021 | ||||
| Note | |||||
| Fixed assets | |||||
| Investments | 800,000 | ||||
| Current assets | |||||
| Cash at bank and in | hand | 93,794 | 525,649 | ||
| Creditors: amounts | falling due within | ||||
| one year | (1,320) | (1,320) | |||
| Net current assets | 92,474 | 524,329 | |||
| Total assets less current liabilities | 892,474 | 524,329 | |||
| Net assets | 892,474 | 524,329 | |||
| Funds ofthe charity | |||||
| Restricted funds | 4,811 | 4,811 | |||
| Unrestncted funds |
887,663 | 519,518 | |||
| Total charity funds | 892,474 | 524,329 |
| Unrestricted | Restricted | Total Funds | |||||
|---|---|---|---|---|---|---|---|
| Funds | Funds | 2021 | |||||
| Donations | |||||||
| Donations | received | - | charitable | purposes | 482,840 | 16,000 | 498,840 |
| Donations | received | - | overheads | 1,766 | 1,766 | ||
| Donations | received | - | gift aid | ||||
| 484,606 | 16,000 | 500,606 |
| Unrestricted | Total Funds | Unrestricted | Total Funds | |||
|---|---|---|---|---|---|---|
| Funds | 2022 | Funds | 2021 | |||
| Obtaining investment |
advice | 1,140 | 1,140 | |||
| Expenditure on charitable |
activities by fund type | |||||
| Unrestricted | Restricted | Total Funds | ||||
| Funds | Funds | 2022 | ||||
| Cancer and cardiovascular | research | 25,866 | 25,866 | |||
| Food security and agricultural | research | 22,763 | 22,763 | |||
| Bacterial research | 23,838 | 23,838 | ||||
| Obesity research | ||||||
| Educational support |
26,686 | 26,686 | ||||
| Neuroscience research |
8,000 | 8,000 | ||||
| Support costs | 4,475 | 4,475 | ||||
| 77,762 | 33,866 | 111,628 | ||||
| Unrestricted | Restricted | Total Funds | ||||
| Funds | Funds | 2021 | ||||
| E | E | |||||
| Cancer and cardiovascular | research | 12,528 | 16,000 | 28,528 | ||
| Food security and agricultural | research | 2,000 | 2,000 | |||
| Bacterial research | 6,700 | 6,700 | ||||
| Obesity research | 7,912 | 7,912 | ||||
| Educational support Neuroscience research |
31,156 15,917 |
31,156 15,917 |
||||
| Support costs | 1,855 | 1,855 | ||||
| 78,068 | 16,000 | 94,068 |
| Grant funding | Total funds | Total fund | |||||
|---|---|---|---|---|---|---|---|
| of activities | Support costs | 2022 | 2021 | ||||
| Cancer and | cardiovascular | research | 25,866 | 25,866 | 28,528 | ||
| Food security and agricultural | research | 22,763 | 22,763 | 2,000 | |||
| Bacterial research | 23,838 | 23,838 | 6,700 | ||||
| Obesity research | 7,912 | ||||||
| Educational | support | 26,686 | 26,686 | 31,156 | |||
| Neuroscience | research | 8,000 | 8,000 | 15,917 | |||
| Governance | costs | 4,475 | 4,475 | 1,855 | |||
| 107,153 | 4,475 | 111,628 | 94,068 |
| Support cost | s | |||||
|---|---|---|---|---|---|---|
| 2022 | 2021 | |||||
| Accountancy | fees | 1,380 | 1,379 | |||
| Legal fees | 2,639 | |||||
| Bank charges | 99 | 90 | ||||
| Computer costs | 357 | 386 | ||||
| 4,475 | 1,855 | |||||
| Independent | examination | fees | ||||
| 2022 | 2021 | |||||
| Fees payable | to the independent | examiner for: | ||||
| Independent | examination | ofthe | financial | statements | 1,320 | 1,320 |
| Intangible | Year ended 5 April 20 assets |
22 |
|---|---|---|
| Website | ||
| development | ||
| Cost | ||
| At 6 April | 2021 and 5 April 2022 | 3,208 |
| Amortisation | ||
| At 6 April | 2021 and 5 April 2022 | 3,208 |
| Carrying | amount | |
| At 5 April | 2022 | |
| At 5 April | 2021 |
| Intangible assets relate to the capitalisation of the des www. medicallifesciences. org.uk Tangible fixed assets |
ign and development of the cha |
rity's website: |
|---|---|---|
| Equipment | Total | |
| Cost | ||
| At 6 April 2021 and 5 April 2022 | 409 | 409 |
| Depreciation | ||
| At 6 April 2021 and 5 April 2022 | 409 | 409 |
| Carrying amount |
||
| At 5 April 2022 | ||
| At 5 April 2021 | ||
| Investments | ||
| Listed | ||
| investments | ||
| Cost or valuation | ||
| At 6 April 2021 | ||
| Additions | 800,000 | |
| At 5 April 2022 | 800,000 | |
| Impairment | ||
| At 6 April 2021 and 5 April 2022 | ||
| Carrying amount |
||
| At 5 April 2022 | 800,000 | |
| At 5 April 2021 |
| 15. | Creditors: amounts | falling | due within one year | ||||
|---|---|---|---|---|---|---|---|
| 2022 | 2021 | ||||||
| F | |||||||
| Accruals and deferred income |
1,320 | 1,320 | |||||
| 16. | Analysis of net assets between funds |
||||||
| Unrestricted | Restricted | Total Funds | |||||
| Funds | Funds | 2022 | |||||
| Investments | 800,000 | 800,000 | |||||
| Current assets | 88,983 | 4,811 | 93,794 | ||||
| Creditors less than | 1 year | (1,320) | (1,320) | ||||
| Net assets | 887,663 | 4,811 | 892,474 | ||||
| Unrestricted | Restricted | Total Funds | |||||
| Funds | Funds | 2021 | |||||
| Investments | |||||||
| Current assets | 520,838 | 4,811 | 525,649 | ||||
| Creditors less than | 1 year | (1,320) | (1,320) | ||||
| Net assets | 519,518 | 4,811 | 524,329 | ||||
| 17. | Financial instruments |
||||||
| The carrying amount |
for each | category of financial | instrument | is as follows: | |||
| 2022 | 2021 | ||||||
| Financial assets measured | at fair value through | income | and expenditure | ||||
| Listed investments | 800,000 | ||||||
| 18. | Related parties |